Another study proved that knocking out GPRC5A suppressed the resistance to gemcitabine in a pancreatic cancer cell line (MIA PaCa-2) [19], and its over-expression enhanced the resistance of ovarian cancer cells [49]. Here, GPRC5A is linked to pancreatic neoplasm.